peritoneal dialysis patients. End-stage renal disease
Conditions
Interventions
Treatment - Drugs
Placebo
Sponsors
Isfahan University of medical Sciences
Eligibility
Sex/Gender
All
Age
21 Years to 100 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: age upper than 21, have history of peritoneal dialysis at least for one month before, having informed consent, no history of carnitine use in previous 8 weeks, no history of infectious disease or fever in previous month. Exclusion criteria: having side effects after taking tablets (like hypertension, dizziness, blurred vision, minimental status, vomiting and diarrhea), person who want to exit from the study,having an infectious problem or antibiotic usage or if a patient change the dialysis method, migrate from the center, having renal transplantation . If a patients need iron complements or Erythropoetin or blood infusion or have gastrointestinal bleeding, exclude from Hemoglobin study.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Albomin. Timepoint: every 3 months. Method of measurement: Bromocresol Green Method. | — |
Secondary
| Measure | Time frame |
|---|---|
| CRP. Timepoint: first month and 9th month. Method of measurement: torbidometry.;Lipid profile ( HDL, LDL, Chol, Triglyceride). Timepoint: first month and 9th month. Method of measurement: Enzymatic and percipitant method.;Homocystein. Timepoint: first month and 9th month. Method of measurement: Elisa.;Hemoglobin. Timepoint: first month and 9th month. Method of measurement: H3. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr Mojgan Mortazavi
Isfahan university of medical scieces, Isfahan kidney diseases research center
Outcome results
None listed